The synthesis of imidazolidin-4-one derivatives of primaquine containing the five-membered ring at the C-terminus of a dipeptide backbone coupled to the parent drug is described. These peptidomimetic derivatives were active against a chloroquine-resistant Plasmodium falciparum strain and inhibited the development of the sporogonic cycle of Plasmodium berghei, affecting the appearance of oocysts in the midguts of the mosquitoes. The novel imidazolidin-4-ones are extremely stable, both in human plasma and in pH 7.4 buffer, as a result of N 1 -acylation. Thus, 'internal' imidazolidin-4-ones derived from dipeptidyl 8-aminoquinolines represent a new entry in antimalarial structure-activity relationships.
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Primaquine, 1, is the only currently available drug that is active against both the latent liver forms of the relapsing malaria caused by Plasmodium vivax and Plasmodium ovale and the gametocytes from all species of parasite causing human malaria. 1 However, primaquine presents a short plasma half-life (ca. 6 h), 2 presumably due to its rapid oxidative deamination to carboxyprimaquine 2.
3-5
Blood toxicity, in particular hemolysis secondary to the ability of primaquine to induce oxidation of oxyhemoglobin to methemoglobin, has also been a source of concern. 6 Peptide and amino acid derivatives of primaquine have been prepared to reduce toxicity of the parent drug as well as to suppress the metabolic pathway leading to 2, 7-10 but many of these derivatives are rapidly hydrolyzed to primaquine by aminopeptidases and endopeptidases. 8, 10 Imidazolidin-4-one formation is often used to protect the N-terminal amino acid residue of peptides and peptidomimetics. 11, 12 Recently, we prepared imidazolidin-4-ones, 3, as potential peptidase-stable prodrugs of amino acid derivatives of primaquine. [13] [14] [15] Compounds 3 displayed gametocytocidal activity against Plasmodium berghei comparable to that of primaquine, as well as activity against P. falciparum asexual stages, while presenting high stability in pH 7.4 buffer (half-lives for hydrolysis typically higher than 12 h). 14, 16 We now set out to incorporate the imidazolidin-4-one moiety into dipeptide derivatives of primaquine, for example, 5 (Scheme 1), both to (i) introduce a terminal basic amino group reported as relevant for activity, 17 and (ii) effectively suppress hydrolysis of the imidazolidin-4-one due to acylation of the N 1 nitrogen atom. We herein report the synthesis and evaluation of the antiplasmodial activity of imidazolidin-4-ones 5 (Scheme 1). DCCI as coupling agent failed to give compounds 6. Similar difficulties were reported for the solid-phase synthesis of Leu-Enkephalin peptidomimetics based on the imidazolidin-4-one scaffold, where resin-bound dipeptide imidazolidin-4-ones containing two methyl groups at C-2 failed to give the desired N 1 -acylated products. 19 Thus, we decided to optimize the coupling reaction of 3a (R 1 = H, R 2 = R 3 = Me) with BocGlyOH. Different cocktails of coupling reagents in DMF were used, of which the most efficient were DIPCDI and HOBt (87% yield of 6a; R 1 = R 4 = H, R 2 = R 3 = Me). 20 The best coupling method (DIPCDI/HOBt) was then assayed in different solvents, with DMF remaining the best, followed by ACN (76% yield) and DCM (34%). Coupling did not take place in THF. These results suggest that the effectiveness of the acylation increases along with the solvent's dielectric constant. When 3a was reacted with bulkier BocAAOH (AA = Ala, Val, Leu, Phe, and Met) using DIPCDI/HOBt in DMF, the resulting compounds 6b-f were obtained only in moderate yield (Scheme 1 and Table 1 ). In contrast, acylation of alaninebased imidazolidin-4-one 3b (R 1 = R 2 = R 3 = Me) proceeded successfully with BocGlyOH to give 6g in moderate yield. Further increase in the size of substituents at the imidazolidin-4-one C-5 position failed to give the corresponding derivatives 6, with exception of 3c (R 1 = CH 2 CH 2 SMe, R 2 = R 3 = Me) that gave 6h in very poor yield (1.6%) by reaction with BocGlyOH. Unfortunately, attempts to prepare the spiro counterparts of 6, starting from imidazolidin-4-ones 3 derived from cyclopentanone or cyclohexanone, were also unsuccessful. Removal of Boc from 6 using 30% TFA in DCM gave compounds 5 almost quantitatively, 21 with the exception of 6h, which decomposed under these conditions. The structure of imidazolidin-4-ones 5 and 6 follows from their spectroscopic data, which reveal the presence of two diastereomers resulting from using racemic primaquine as starting material. For example, the imidazolidin-4-one C-2 methyl proton signals of 6, 5b-g appear as two sets of two singlets (1:1:1:1 integration). 22 Similarly, the two methyl groups at C-2 appear as four signals in the 13 C NMR spectra (cf. Supporting Information). The 1 H NMR signal of the C-5 CH 2 of 6, 5a-f indicates the diastereotopic nature of the two protons, which appear as an AB system at d ca. 4 ppm, with 2 J = 14-16 Hz. All attempts to separate the two diastereomers using column chromatography, flash chromatography, and preparative TLC were unsuccessful. Moreover, reverse-phase HPLC using Merck's RP-8 and RP-18 columns (both 125 and 250 mm) consistently gave single peaks for each derivative 5b-g (not shown), indicating that both diastereomers display similar properties, making their separation extremely difficult to achieve by standard methods. The same separation problem had already been observed for precursor compounds 3 and dipeptide derivatives of primaquine. 10, [13] [14] [15] [16] 18 Imidazolidin-4-ones 5a-g were evaluated against the chloroquine-resistant P. falciparum strain W2, and IC 50 values obtained are given in Table 1 , together with those previously determined 15 for the parent drug, 1, and also for precursors 3a and 3b. IC 50 values for 5 range from 5.5 to 12 lM, with one compound (5g) displaying activity close to that of primaquine, 1 (3.3 lM). Inspection of the data in Table 1 shows that antiplasmodial activity is slightly affected by the nature of substituents R 4 in the N-terminal amino acid moiety. For example, the glycyl derivative 5a (R 1 = R 4 = H) is equipotent with its leucyl counterpart 5d (R 1 = H, R 4 = i Bu) and ca. two times more active than its methioninyl counterpart 5f (R 1 = H, R 4 = CH 2 CH 2 SMe), thus suggesting that large hydrophobic not have a marked influence on activity against P. falciparum: changing H for Me at R 1 (i.e., 5a vs 5g) leads only to a marginal increase in activity. Although these SARs are based on diastereomeric mixtures, it should be noted that the enantiomers of primaquine are equipotent antimalarials. 23 Compounds 5 are generally more active than their N-terminal imidazolidin-4-one precursors 3, particularly when R 1 = Me, as
shown by at least 10-fold difference in IC 50 values against P. falciparum between the alanine-based imidazolidin-4-one 3b and its N 1 -glycyl derivative 5g. This result is consistent with the previously mentioned relevance of a free primary amino group for antiplasmodial activity. 17 The potential of compounds 5a, b, e to prevent the transmission of malaria was studied using a model consisting of BalbC mice infected with P. berghei and Anopheles stephensi mosquitoes and compared to that of primaquine.
14, 24 The antimalarial activity was assessed based on the percentage of mosquitoes with oocysts and the mean number of oocysts per infected mosquito (Table 2 ). Although this model cannot specifically attribute the drug effect to either gametocytocidal or sporontocidal activity, it can clearly show if a compound is effective at interrupting the transmission of the infection to mosquitoes by interference with the cycle in these insects. 25, 26 Compounds 5a, e significantly reduced (P < 0.05) the sporogonic development of P. berghei at 10 and 50 lmol/kg when compared with the control, though they did not completely inhibit the production of oocysts at 50 lmol/kg. Compound 5b was inactive at 10 lmol/kg.
The decomposition of compounds 5 was studied in non-enzymatic and enzymatic conditions using HPLC. No traces of products resulting from either imidazolidin-4-one ring-opening (i.e., dipeptide derivatives of primaquine) or N-terminal amino acid hydrolysis (i.e., compounds 3) were detected when incubated in pH 7.4 buffer and 80% human plasma at 37°C. This result confirms our initial prediction, that is, N 1 -acyl imidazolidin-4-ones have negligible susceptibility to hydrolysis.
In conclusion, the synthesis of imidazolidin-4-one derivatives of primaquine, 5, was attained by solution phase acylation of imidazolidin-4-one precursors 3 with Boc-protected amino acids. Compounds 5 exhibit moderate activity against a chloroquineresistant strain of P. falciparum and inhibit the transmission of the infection to mosquitoes as efficiently as primaquine. Useful information concerning the effect of R 1 and R 4 on the bioactivity of 5 could be established, despite the obvious limitations imposed by the relatively small number of compounds included in this preliminary study. The high aqueous stability displayed by 5 suggests that incorporation of an imidazolidin-4-one moiety into the C-terminus of a dipeptide derivative of primaquine might be a useful approach to obtain chemically and enzymatically stable peptidomimetic derivatives of 8-aminoquinoline antimalarials. Recent reports indicate that adequate substitution at the C-2, C-4, and C-5 positions of the quinoline moiety can lead to potent 8-aminoquinoline blood-schizontocidal antimalarials devoid of significant blood toxicity. 27 Therefore, combination of the imidazolidin-4-one scaffold with the appropriately substituted quinoline moiety deserves further attention. 
